- Home
- MKTW vs ONCY Comparison
MKTW vs ONCY Comparison
Compare MKTW & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- ONCY
- Stock Information
- Founded
- MKTW 1999
- ONCY 1998
- Country
- MKTW United States
- ONCY Canada
- Employees
- MKTW N/A
- ONCY N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- ONCY Pharmaceuticals and Biotechnology
- Sector
- MKTW Technology
- ONCY Health Care
- Exchange
- MKTW Nasdaq
- ONCY Nasdaq
- Market Cap
- MKTW 48.2M
- ONCY 49.1M
- IPO Year
- MKTW N/A
- ONCY 1999
- Fundamental
- Price
- MKTW $17.30
- ONCY $0.34
- Analyst Decision
- MKTW
- ONCY Strong Buy
- Analyst Count
- MKTW 0
- ONCY 4
- Target Price
- MKTW N/A
- ONCY $4.33
- AVG Volume (30 Days)
- MKTW 27.9K
- ONCY 889.1K
- Earning Date
- MKTW 05-08-2025
- ONCY 07-31-2025
- Dividend Yield
- MKTW 4.13%
- ONCY N/A
- EPS Growth
- MKTW 207.28
- ONCY N/A
- EPS
- MKTW 3.12
- ONCY N/A
- Revenue
- MKTW $383,217,000.00
- ONCY N/A
- Revenue This Year
- MKTW N/A
- ONCY N/A
- Revenue Next Year
- MKTW $0.42
- ONCY N/A
- P/E Ratio
- MKTW $5.77
- ONCY N/A
- Revenue Growth
- MKTW N/A
- ONCY N/A
- 52 Week Low
- MKTW $9.08
- ONCY $0.33
- 52 Week High
- MKTW $29.00
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- MKTW 60.15
- ONCY 25.45
- Support Level
- MKTW $16.19
- ONCY $0.37
- Resistance Level
- MKTW $18.78
- ONCY $0.37
- Average True Range (ATR)
- MKTW 0.96
- ONCY 0.04
- MACD
- MKTW -0.11
- ONCY -0.01
- Stochastic Oscillator
- MKTW 55.95
- ONCY 4.95
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.